Arteris’ Q4 Beat Was Not the Story; the 2026 Contract Ramp Is What Bears Must Underwrite

The clean read from this print is that Arteris is no longer only an IP recovery story tied to quarterly license timing; it is becoming a contracted-revenue compounding story where the street may be underweighting the forward book relative to the current P&L. What was priced in was modest growth and ongoing losses: consensus sat at $18.5 million of Q4 revenue and -$0.08 of EPS. What actually surprised was not just the $20.1 million actual revenue, which was +8.6% above estimate, or the -$0.05 EPS, which was +37.5% better than estimate, but the combination of $83.6 million ACV plus royalties exiting the quarter, $117 million of RPO, and 2026 revenue guidance of $89 million to $93 million. The variant perception is that investors focused on GAAP EPS of -$0.19 in the quarterly history will miss the operating leverage embedded in the company’s own non-GAAP account, where Q4 non-GAAP net loss was $2.3 million and full-year free cash flow was positive $5.3 million. That distinction matters because Arteris’ model is priced off contracted design activity before it fully appears in reported revenue.

The quarterly trajectory supports that view because Q4 was the first period in the supplied history where revenue cleared $20.1 million after staying between $12.5 million and $17.4 million for the prior eight quarters. The cadence changed visibly: Q4 FY2025 revenue grew +15.7% sequentially and +30.0% year-over-year, compared with Q3 FY2025 at +5.5% sequentially and +18.3% year-over-year. Gross margin also moved back to 90.8% in Q4 FY2025, matching Q1 FY2025’s 90.8% and above Q3 FY2025’s 89.9%, which means the Q4 revenue acceleration did not require a gross-margin concession on the GAAP basis shown in the quarterly history. The apparent conflict is Q1 FY2026 in the quarterly history, where revenue rises again to $22.9 million with +13.9% sequential growth and +38.7% year-over-year growth, but gross margin falls to 83.0%. That tells PMs not to extrapolate Q4’s 90.8% margin mechanically into every quarter; it also says the revenue growth is coming through even when mix or acquisition accounting pressures gross margin. The right debate is therefore not whether the company can produce a single clean quarter, but whether $83.6 million of ACV plus royalties and $117 million of RPO make the next step-up durable enough to absorb the margin variability.

That durability is what the street comparison understates, because the beat was on Q4 reported expectations while the real repricing input is the 2026 guide. Nicholas Hawkins framed Q4 in the company’s own reporting basis as: “Total revenue for the fourth quarter was $20.1 million, up 16% sequentially and 30% year-over-year and above the top end of our guidance range.” The wording matters because “above the top end” is a management-guide beat, separate from the street beat of +8.6%, and it confirms the upside was not only a sell-side estimate issue. For FY2025, Hawkins gave $70.6 million of total revenue, 22% higher year-over-year, and management’s FY2026 revenue range of $89 million to $93 million therefore puts the company into a materially different revenue scale. The $91 million midpoint is explicitly in the transcript, and Hawkins separated the acquired and original businesses by saying, “So $84 million is the Arteris original business, and that represents about a 19% year-over-year growth.” That sentence earns attention because it limits the bear argument that 2026 is just Cycuity inorganic revenue: approximately $7 million comes from Cycuity, while the original business is still guided to about a 19% year-over-year growth rate.

The contract metrics are the strongest evidence that the revenue guide is not aspirational. Karel Janac said Q4 delivered “yet another record annual contract value plus royalties of $83.6 million, which represents a 28% year-on-year increase,” and Hawkins added that RPO totaled $117 million, representing a 32% year-over-year increase. These two numbers are the core of the long thesis because they sit upstream of reported revenue and are both growing faster than FY2025 revenue’s 22% full-year growth. If ACV plus royalties exits 2026 at $100 million to $104 million, as guided, then the company is asking investors to underwrite another step-up from the $83.6 million Q4 FY2025 exit level while also converting enough of the $117 million RPO into reported revenue to reach $89 million to $93 million. The risk is not that the print lacks proof; the risk is that investors apply a loss-making software multiple to a business whose leading indicators have already moved to record levels. In semiconductor IP, that misclassification can persist until royalty and ratable components make the P&L cleaner, but the Q4 data argue the inflection is already visible in bookings and obligations.

The profitability bridge is more nuanced, which is why the stock reaction should be judged against operating-loss and free-cash-flow guidance rather than GAAP EPS alone. On the company’s own account, Q4 non-GAAP gross profit was $18.5 million at a gross margin of 92%, while GAAP gross profit was $18.3 million at a gross margin of 91%. The quarterly-history table shows 90.8% GAAP gross margin for Q4 FY2025, so there is a basis distinction, but all three figures point to a high-gross-margin revenue stream. The pressure sits below gross profit: Q4 non-GAAP operating expense was $20.8 million, and GAAP operating expense was $26.7 million, including acquisition-related expenses of $1.4 million. Full-year non-GAAP operating expense was $77.2 million, an increase of 14% from the prior year, while full-year revenue rose 22%. That spread is the operating-leverage fact in the print. The model is still loss-making, with a Q4 non-GAAP operating loss of $2.2 million and full-year non-GAAP operating loss of $12.5 million, but the full-year non-GAAP operating loss improved by $2.4 million from the prior year. The market may be missing that the expense base is growing slower than revenue before the 2026 ACV step-up has fully landed.

Cash flow adds another layer to the variant view because Arteris is not funding the growth solely through worsening losses. Hawkins said free cash flow, including capital expenditure, was positive $3 million in Q4 and positive $5.3 million for the full year, close to the top end of guidance. For Q1 FY2026, management guided non-GAAP free cash flow of negative $1.5 million to positive $1.5 million, so there can be quarterly volatility, but the full-year FY2026 guide calls for positive $5 million to positive $9 million. That matters because it separates Arteris from earlier-stage IP vendors where bookings growth often comes with cash burn. The company also guided FY2026 non-GAAP operating loss of between $9 million to $5 million, approximately $1 million of which is expected to be related to the Cycuity acquisition. Against full-year FY2025 non-GAAP operating loss of $12.5 million, the direction is clear: the company is guiding improvement even while absorbing Cycuity and aiming for $89 million to $93 million of revenue. The GAAP full-year operating loss of $33.1 million and GAAP net loss of $34.7 million remain the bear case, but those figures include a cost structure and acquisition effects that are not the same signal as positive full-year free cash flow of $5.3 million.

The near-term guide is the one place where PMs should avoid overfitting the Q4 beat, because management’s Q1 FY2026 revenue range of $20.5 million to $21.5 million sits only modestly above Q4’s $20.1 million street-comparison actual. Hawkins’ exact commitment was: “For the first quarter of 2026, we expect ACV plus royalties of $85 million to $89 million, revenue of $20.5 million to $21.5 million, with a non-GAAP operating loss of $3.5 million to $2.5 million and non-GAAP free cash flow of negative $1.5 million to positive $1.5 million.” The important part is not the low sequential revenue step from Q4 to Q1; it is that ACV plus royalties is guided to move from $83.6 million at Q4 exit to $85 million to $89 million in Q1. If Q1 lands inside that ACV band while revenue stays within $20.5 million to $21.5 million, then the contract base is still compounding even if recognized revenue timing is not linear. If Q1 ACV misses $85 million, the thesis weakens because the 2026 exit target of $100 million to $104 million would require a steeper catch-up over the remaining quarters.

The tone of the call also shifted in a way that supports, rather than substitutes for, the numerical thesis. The tone history shows Q1 FY2026 sentiment at 0.45 versus Q4 FY2025 at 0.40, guidance_tone at 0.34 versus 0.19, and uncertainty down to 34.8 from 58.5. That is not just management sounding better after a beat; the tone_confidence edged to 0.53 from 0.52, while ai_optimism rose to 0.46 from 0.40. The most useful change is the uncertainty delta of -23.7, because it aligns with the hard guidance bands for Q1 and FY2026 rather than floating above them. Prepared and Q&A sentiment are available for Q1 FY2026 at 0.49 and 0.49, which means the delivery did not deteriorate under analyst questioning. The conflict is that Q4 FY2025 prepared_sentiment and qa_sentiment are n/a, so the cleanest comparison is on aggregate sentiment, guidance_tone, tone_confidence, ai_optimism, and uncertainty. Those all moved in the right direction from Q4 FY2025 to Q1 FY2026, and the lower uncertainty reading is consistent with management being willing to put $100 million to $104 million on the ACV-plus-royalties exit line.

The competitive comparison sharpens the point that Arteris is not trying to win by matching the scale of the largest EDA and IP names; it is trying to compound from a smaller revenue base with margins that resemble IP economics. In the peer table, SNPS reported $2,276.0 million of revenue with 72.3% gross margin and +41.9% revenue YoY, CDNS reported $1,474.2 million with 95.8% gross margin and +18.7% revenue YoY, and ARM reported $1,490.0 million with 93.1% gross margin and +20.1% revenue YoY. Arteris’ Q4 FY2025 revenue of $20.1 million is a fraction of those peers, but its 90.8% gross margin in the quarterly history and 30.0% revenue YoY sit much closer to an IP-quality model than the absolute revenue base suggests. The market’s likely mistake is to penalize Arteris for subscale losses without giving credit for a gross-margin profile that is already near ARM’s 93.1% and above SNPS’s 72.3%, while revenue YoY of +30.0% is above CDNS’s +18.7% and ARM’s +20.1%. Scale remains the missing piece, but the Q4 and 2026 guide indicate scale is arriving through ACV and RPO rather than a one-time license spike.

The supply-chain read-through is unusually sparse because the data pack lists no named customers of AIP and no named suppliers to AIP, so there is no defensible company-specific customer or supplier trade to draw from this print. That absence itself matters for portfolio construction: investors should not infer a direct quarterly read-through to any named semiconductor customer, foundry, EDA vendor, or IP supplier from the supplied data. The only named second-order implications that can be grounded are competitive. For SNPS, CDNS, and ARM, Arteris’ 30.0% Q4 revenue YoY and FY2026 original-business guide of about 19% year-over-year growth indicate that a smaller interconnect and system IP vendor is still expanding despite incumbents with 72.3%, 95.8%, and 93.1% gross margins, respectively. The magnitude is not that Arteris is taking measured share from those firms, because the data do not provide share; the magnitude is that Arteris is guiding $84 million for the original business in 2026 while exiting 2026 at $100 million to $104 million of ACV plus royalties including Cycuity. That is the competitive wedge PMs can underwrite without inventing a customer logo.

The key objection is the gross-margin drop visible in Q1 FY2026 quarterly history, and it should be taken seriously because 83.0% is well below Q4 FY2025’s 90.8%. But the rest of the Q1 FY2026 line cuts against a simple deterioration story: revenue is $22.9 million, revenue QoQ is +13.9%, revenue YoY is +38.7%, and diluted EPS improves to -$0.17 from -$0.19 in Q4 FY2025. In other words, the margin line worsens while revenue and EPS improve. That pattern is consistent with mix or acquisition impacts rather than a broad breakdown in unit economics, especially given management’s FY2026 non-GAAP free cash flow guide of positive $5 million to positive $9 million. The burden of proof in the next print is therefore not whether gross margin snaps back to 90.8%, but whether lower gross margin still comes with the promised operating-loss range, cash generation, and ACV progression. If those hold, the multiple should follow contracted growth rather than one quarter’s gross-margin mix.

What to watch next is concrete. For Q1 FY2026, the thesis is confirmed if revenue lands within or above $20.5 million to $21.5 million, ACV plus royalties lands within or above $85 million to $89 million, non-GAAP operating loss stays within the guided $3.5 million to $2.5 million range, and free cash flow stays within negative $1.5 million to positive $1.5 million. It is strengthened if the company keeps FY2026 revenue guidance at $89 million to $93 million, preserves the $100 million to $104 million ACV-plus-royalties exit target, and keeps FY2026 free cash flow at positive $5 million to positive $9 million. It breaks if Q1 ACV plus royalties falls below $85 million, because that would pressure the path from $83.6 million at Q4 FY2025 to $100 million to $104 million at the 2026 exit; it also breaks if the original-business contribution is revised below $84 million or if Cycuity’s approximately $7 million contribution becomes the only source of revenue growth. The date anchor is the next quarterly report after the 2026-02-12 call: by that print, investors should demand evidence that the Q4 beat was the first visible quarter of a contracted ramp, not merely a revenue pull-forward against a still-subscale expense base.